Dr. Reddy's Laboratories Limited (DRREDDY.BO)
BSE - BSE Real-time price. Currency in INR
Add to watchlist
At close: 03:29PM IST
| Previous close | 6,095.10 |
| Open | 6,056.20 |
| Bid | 6,087.05 x 0 |
| Ask | 6,088.85 x 0 |
| Day's range | 6,038.45 - 6,114.80 |
| 52-week range | 4,864.25 - 6,505.50 |
| Volume | |
| Avg. volume | 15,483 |
| Market cap | 1.013T |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 18.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 40.00 (0.66%) |
| Ex-dividend date | 15 Jul 2024 |
| 1y target est | N/A |
- Business Wire
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
HYDERABAD, India, June 03, 2024--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
- Business Wire
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
HYDERABAD, India, May 28, 2024--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
- Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, India & REYKJAVIK, Iceland, May 21, 2024--Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva®.
© 2024 Yahoo. All rights reserved.